Abbott Laboratories vs American States Water Company — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while American States Water Company trades at $87.85 (market cap $3.47B). The key difference: Abbott Laboratories is far larger — about 54.2× American States Water Company's market cap, and American States Water Company pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| ABT | AWR | |
|---|---|---|
Market Cap | $187.95B | $3.47B |
Sector | Health | Utilities |
52-Week High | $136.62 | $89.28 |
52-Week Low | $82.57 | $70.10 |
Enterprise Value | $214.96B | $4.37B |
Dividend Yield | 2.32% | 2.49% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
American States Water (AWR) trades at $87.45, up 1.02% with a bullish technical outlook. The company reported strong Q2 2026 earnings of $1.09 per share, beating estimates, driven by water rate increases and revenue growth of 11.2%. Profitability remains robust with a 20.52% net income margin and ROE of 13.62%. Recent news highlights AWR's 71-year dividend growth streak and inclusion in TIME's America's Best Companies 2026 list.
AWR offers stable income with consistent dividend growth but faces valuation concerns at 23.92 P/E. Analyst consensus is cautious with 50% hold ratings. Key risks include regulatory dependence and competitive pressures. The stock presents a defensive play with reliable dividends but limited near-term upside given current multiples.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →